Elucidate Understanding of RAS Immune Evasion, Exploit Novel Modalities from Degradation & PAN-RAS Inhibition & Effectively Treating Cancers Beyond Lung & Guaranteeing the Clinical Validation of Valuable RAS-Targeted Medicines

Welcome to the 6th Annual RAS-Targeted Drug Development Summit

Uniting Large Pharma, Innovative Biotech & Leading Academics to Defeat the Holy Grail Target in Precision Oncology

With tumor and patient heterogeneity, the quest to target the remaining RAS mutants continues, and now more than ever, we are witnessing this industry make great strides in utilizing novel modalities and elucidating mechanisms of resistance. However, treating patients with RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the depth and durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.

Owing to this, the 6th Annual RAS-Targeted Drug Development Summit returns as the central hub dedicated to every aspect of discovery and development of RAS, from discovery and clinical development through to commercialization, equipping 250+ global RAS leaders with the means to create effective frontline RAS therapies for better patient outcomes.

What’s New for 2024?

Default Square (4)

Extensive technical content covering the latest advancements in identifying, validating and clinically progressing pan-RAS and selective inhibitors, vertical and parallel pathway targeting small molecules, cancer vaccines and cell therapies with improved potency and selectivity.

Default Square (5)

A new cohort of expert speakers and organizations presenting from the likes of Genfleet Therapeutics, Inspirna, Anocca, Bayer, Elicio Therapeutics, Frontier Medicines, Ranok Therapeutics, Ipsen Pharma and more.

Default Square (3)

Expert-led pre-conference workshops delving into the hottest aspirations of the precision oncology community, including the debate surrounding targeting wildtype RAS, how to overcome acquired resistance and how to inform combinations regimes in and before the clinic.

2024 Expert Speakers Include:

A Snapshot of 2023 Attendees

Our 2024 Partners:

Hear What Our Past Attendees Have to Say:

“The summit provides an unparalleled platform to discuss the latest breakthroughs in RAS research and clinical development, making it a valuable resource for anyone seeking to stay up-to-date on this critical area of oncology ”

- Lifecyle Leader, KRAS, Roche

"This conference is an exciting and unique opportunity to learn about the latest advancements in RAS research and clinical developments”

- Director, Clinical Biomarkers & Diagnostics, Amgen

The 5th RAS Targeted DD Summit brings experts from both academia and industry together to exchange learnings and further brainstorm on how to tackle this important oncogene - Saskia Brachmann, Associate Director &
Senior Global Project Lead, Novartis

- Saskia Brachmann, Associate Director & Senior Global Project Lead, Novartis

"The 5th RAS Targeted DD Summit is an extraordinary event to strengthen a trusted network of experts in the field of RAS both from academia and industry”

- Chiara Ambrogio, Associate Professor of Molecular Biology, University of Torino